Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that Ryan Dunlap, Vice President and Chief Financial Officer, will present a corporate update at the Marcum MicroCap Conference. The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. ET at The Grand Hyatt Hotel in New York City. Galena Biopharma Inc (NASDAQ:GALE) weekly performance is 5.99%. On last trading day company shares ended up $2.30. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is -3.61%.
ZIOPHARM Oncology, Inc (NASDAQ:ZIOP) a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. The presentation, titled “Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Immunotherapy,” was presented in an oral session at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 21-24 in Washington, DC. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares advanced 7.69% in last trading session and ended the day on $3.36. Its return on assets is -102.80%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) quarterly performance is -23.29%.
BioDelivery Sciences International (NASDAQ:BDSI) was upgraded by equities researchers at TheStreet from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Stock Ratings News reports. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares moved up 6.26% in last trading session and was closed at $9.33, while trading in range of $8.75 – $9.47. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) year to date (YTD) performance is 58.40%.
On May 20, Prosensa Holding N.V. (NASDAQ:RNA) reported financial results for the first quarter ending March 31, 2014 and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD). Revenue for the three months ended March 31, 2014 was EURO14.8 million, compared with EURO2.4 million in 2013. Net income for the three months ended March 31, 2014 was EURO7.3 million or EURO0.20 per share (EURO0.19 diluted income per share), compared to a loss of EURO3.5 million or EURO0.12 per share (EURO0.12 diluted loss per share), for the comparative period in 2013. Prosensa Holding NV (NASDAQ:RNA) ended the last trading day at $8.41. Company weekly volatility is calculated as 10.64% and price to cash ratio as 2.69. Prosensa Holding NV (NASDAQ:RNA) showed a positive weekly performance of 37.87%.
O May 1, Vical Incorporated (NASDAQ:VICL) reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter of 2014 was $3.5 million, or $0.04 per share, compared with a net loss of $9.3 million, or $0.11 per share, for the first quarter of 2013. Revenues for the first quarter of 2014 were $2.4 million, compared with revenues of $1.6 million for the first quarter of 2013, reflecting higher payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical’s therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. Vical Incorporated (NASDAQ:VICL) on last trading day company shares ended up $1.23. Analysts mean target price for the company is $3.23. Vical Incorporated (NASDAQ:VICL) distance from 50-day simple moving average (SMA50) is -1.76%.